Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companys product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinsons diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Company website - http://www.sagerx.com O/S = 37.35M Float = 35.63M Institutions = 94.00% Insiders = 18.50% PT Raised $95 - $110 https://www.marketbeat.com/stocks/NASDAQ/SAGE/ 6/17 - Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression - https://finance.yahoo.com 5/17 - Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder https://finance.yahoo.com/news/sage-therapeutics-receives-fast-track-110000509.html
This has been a pretty good swing/day trading stock this year and missed a real nice move on Friday but expect more to come
Have not been playing this week (Holiday stuff) & just got around to checking stocks & VERY nice surprise here BUT sold most of my position on last pop & only kept a few shares so not as nice as it woulda been!!
have been watching this come down & thought about picking up some yesterday but didn't so missed ride up but not ride down!
ER coming up 5/3 - Sage Therapeutics asks FDA to approve lead drug for postpartum depression - https://finance.yahoo.com/m/61fb028e-f471-30b6-a7b3-40dff329f607/sage-therapeutics-asks-fda-to.html
Sage gets expedited development plan for SAGE-217 in major depressive disorder, postpartum depression; needs one additional pivotal trial in MDD, where CEO says “we are exploring the potential for pts... to feel well within days” - http://investor.sagerx.com/news-rel...s-pivotal-phase-3-trial-status-sage-217-major
Looking like a decent spot to try for another bounce here. Easily potential for 20% gains. I'd like to see a dip closer to $140 first and meet up with the uptrending 200MA to act as some more support.
Bounced today 5%, will have to keep stalking for another week or 2 to see if it presents a good entry
Doing some dd & going back through some of my watch lists only to see that i am way late to this little party Should have checked in on this much sooner after my return from no man's land - nice dip down to $80's 12/18 & up real nice this month.
